Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for IXICO in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 83.55.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in IXICO.
IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services in the fields of Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, And Progressive Supranuclear Palsy, Spinocerebellar Ataxia, and Friedreich's Ataxia diseases, as well as other movement disorders and dementias; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.